Severe Hemophilia A Clinical Trial
Official title:
Immunogenicity, Efficacy and Safety of Treatment With Human-cl-rhFVIII in Previously Untreated Patients With Severe Hemophilia A
Investigate the inhibitor development rate of Human cl rhFVIII in previously untreated patients with severe Hemophilia A.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT01051544 -
Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive
|
N/A | |
| Completed |
NCT02172950 -
An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A
|
Phase 3 | |
| Completed |
NCT01051076 -
Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)
|
N/A | |
| Completed |
NCT03376516 -
Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A
|
Phase 3 | |
| Completed |
NCT01181128 -
Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A
|
Phase 3 | |
| Completed |
NCT02083965 -
Pharmacokinetics of rFVIIIFc at Two Vial Strengths
|
Phase 1 | |
| Completed |
NCT01085344 -
Canadian Hemophilia Prophylaxis Study
|
Phase 4 | |
| Completed |
NCT04864743 -
A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
|
Phase 1 | |
| Completed |
NCT01341912 -
Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)
|
Phase 3 | |
| Completed |
NCT01125813 -
Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A
|
Phase 3 | |
| Active, not recruiting |
NCT05181618 -
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
|
Phase 4 | |
| Terminated |
NCT04046848 -
Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A
|
Phase 1/Phase 2 | |
| Completed |
NCT06137092 -
rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study
|
Phase 3 | |
| Terminated |
NCT01405742 -
Hemophilia Adult Prophylaxis Study
|
Phase 3 | |
| Active, not recruiting |
NCT04431726 -
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors
|
Phase 3 | |
| Recruiting |
NCT05935358 -
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
|
Phase 4 | |
| Recruiting |
NCT06142552 -
Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
|
Phase 3 | |
| Not yet recruiting |
NCT06136507 -
Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A
|
Phase 3 | |
| Completed |
NCT02954575 -
Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A
|
Phase 3 | |
| Completed |
NCT01027377 -
Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A
|
Phase 1 |